In response to media reports that a glass of wine 'cuts risk of gullet cancer'taken from two authoritative studies reported in the magazine Gastroenterology 136, issue 3 March 2009: The newly launched Barrett's Oesophagus Campaign - the only charity dedicated to the prevention

In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors( PPIs ). However it has not hitherto been fully determined whether differences in the onset of antisecreatary activity may affect the speed of symptom relief with different PPI. Dr. Ri-Nan Zheng from China addresses this question.

Drinking one glass of wine a day may lower the risk of Barrett's Esophagus by 56 percent, according to a new study by the Kaiser Permanente Division of Research in the March issue of Gastroenterology. Barrett's Esophagus is a precursor to esophageal cancer, the nation's fastest growing cancer with an incidence rate that's jumped 500 percent in the last 30 years.

Additional study suggests drinking alcohol in early adulthood may increase reflux esophagitis risk Although the relationship between alcohol and esophageal squamous cell carcinoma is well established, studies investigating the association between alcohol intake and reflux esophagitis (RE), Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) have reported inconsistent findings.

A national leader in incision-free surgery performed through natural orifices, the Center for Scarless Surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center is now offering patients with severe, chronic acid reflux disease a unique incision-free procedure called TIF, or transoral incisionless fundoplication.

More than 20 million Americans suffer from gastroesophageal reflux disease (GERD), experienced by many as chronic heartburn. Medication offers short-term relief for some sufferers of this disease. For those seeking a non-prescription alternative, a magnetic device, currently being evaluated at UC San Diego Medical Center, may provide a long-term solution.

Recent reports have indicated that recurrent chest pain is often a result of esophageal motility disorders or gastroesophageal reflux diseases (GERD), which is known as esophageal chest pain. However, very few studies have been performed about esophageal manometric studies, 24-h intra-esophageal pH monitoring and a Holter electrocardiography for the differential diagnosis of chest pain caused by esophageal dysfunctional and/or myocardial ischemia. A research team led by Prof.

Respiratory Technology Corporation (dba Restech) announced that its revolutionary Dx-pH Measurement System has received CE mark approval, allowing introduction to the European Union and all countries recognizing the CE Mark. This approval from the European Union certifies Restech has met EU health, safety and environmental requirements that ensure consumer safety.

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX? (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.

Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new tablet formulation to add to its ZEGERID? family of branded prescription pharmaceutical products. The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor (PPI), with a mix of buffers.